Sibrotuzumab - CISMeF

Preferred Label : Sibrotuzumab;

NCIt synonyms : HuMoAb F19; Humanized F19 Monoclonal Antibody;

NCIt definition : A humanized monoclonal antibody (MoAb) against human fibroblast activation protein (FAP). FAP is a 95 kDa cell surface glycoprotein and an inducible tumor stromal antigen of epithelial cancers and of a subset of soft tissue sarcomas. FAP shows a very limited distribution pattern in normal tissues, thereby sibrotuzumab has possible diagnostic and therapeutic applications in epithelial cancers.;

UNII : 552U6E1NIW;

CAS number : 216669-97-5;

NCI Metathesaurus CUI : CL563157;

Détails

Origin ID

C156438;

UMLS CUI

C1260215;

Currated CISMeF NLP mapping
- sibrotuzumab [MeSH Supplementary Concept]
- sibrotuzumab [MeSH concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- sibrotuzumab [MeSH concept]
- sibrotuzumab [MeSH Supplementary Concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients